Dr Reddys Laboratories announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Dr. Reddy's Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
